Treating myeloproliferation - on target or off?

New England Journal of Medicine

Volumn 373, Issue 10, 2015, Pages 965-966

  Armanios, Mary ^a,b   Greider, Carol W ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMETELSTAT; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; TELOMERASE; TOLL LIKE RECEPTOR 9; INDOLE DERIVATIVE; NICOTINAMIDE;

BLEEDING TENDENCY; BONE MARROW SUPPRESSION; CELL DEATH; DRUG RECEPTOR BINDING; DRUG RESPONSE; EDITORIAL; ENZYME INHIBITION; EXTRAMEDULLARY HEMATOPOIESIS; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER TOXICITY; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOMATIC MUTATION; SYMPTOMATOLOGY; TELOMERE SHORTENING; THROMBOCYTHEMIA; THROMBOCYTOPENIA; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

FEMALE; HUMANS; INDOLES; MALE; NIACINAMIDE; PRIMARY MYELOFIBROSIS; TELOMERASE; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84940839762     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1508740     Document Type: Editorial

References (10)

1. Stein BL, Moliterno AR. Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation. JAMA 2010; 303: 2513-8.
2. Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med 2015; 373: 920-8.
3. Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 2015; 373: 908-19.
4. Ouellette MM, Wright WE, Shay JW. Targeting telomeraseexpressing cancer cells. J Cell Mol Med 2011; 15: 1433-42.
5. Chiappori AA, Kolevska T, Spigel DR, et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann Oncol 2015; 26: 354-62.
6. Genetic Engineering and Biotechnology News. Geron halts one imetelstat trial; another 'doubtful' to advance. September 10, 2012 (http://www.genengnews.com/gen-news-highlights/geron-halts-one-imetelstat-trial-another-doubtful-to-advance/81247293).
7. Stanley SE, Armanios M. The short and long telomere syndromes: paired paradigms for molecular medicine. Curr Opin Genet Dev 2015; 33: 1-9.
8. Aubert G, Hills M, Lansdorp PM. Telomere length measurement-caveats and a critical assessment of the available technologies and tools. Mutat Res 2012; 730: 59-67.
9. Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol 2015; 43: 78-89.
10. Greider CW. Telomeres, telomerase and senescence. Bioessays 1990; 12: 363-9.